openPR Logo
Press release

Creative Diagnostics Introduces the Launch of Beta Actin Antibody

03-04-2021 11:08 AM CET | Science & Education

Press release from: Creative Diagnostics

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently expanded antibody portfolio with the launch of a series of beta actin antibody for ICC/IF, WB, and IHC-P. These new products are only for research use, and are not intended for diagnostic use.

Creative Diagnostics offers primary antibodies to multiple forms of virtually every protein in the proteome, and secondary antibodies that are available targeting all common research species and are conjugated with multiple types of enzymes and fluorescence, as well as control antibodies to make sure researchers generating data with confidence. Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. The anti beta actin monoclonal antibodies can be used to detect beta-actin, which is one of six different actin proteins.

For example, Anti-ACTB monoclonal antibody (DCABH-10282), one of the products included in this release, is mouse anti-Human ACTB monoclonal antibody that can be used for ICC/IF, WB, and IHC-P. This antibody can specifically recognize beta actin in tissues or species through immunoblotting, immunofluorescence staining of cultured cell lines, and immunohistochemistry.

"Creative Diagnostics is committed to developing and delivering high quality research tools and solutions to the life science community, and we're so glad to advance our clients' scientific discoveries and accelerate their next breakthrough by continuously offering such monoclonal antibodies. Our mouse monoclonal antibody to beta actin is now available for global researchers, and more improved antibodies and services will be offered to meet the unmet needs of scientists working in basic research and development." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

"Creative diagnostics offers a wide range of high quality antibodies validated for use in multiplexed assays. Beta actin antibodies are highly complementary to our existing antibody offerings and will further help us meet the continuing demands from our customers for high quality antibodies. We'll continue to work to develop more antibody products and customized services for researchers in the future." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about beta actin antibodies or other research materials, please visit Creative Diagnostics at

NY 11967, USA

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Introduces the Launch of Beta Actin Antibody here

News-ID: 2251851 • Views: 417

More Releases from Creative Diagnostics

Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support …
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of several Monkeypox Virus Antibodies and Antigens that have been validated to work in various types of immunoassays and can be used as tools for the detection of Monkeypox viruses. Monkeypox virus (MPV or MPXV) is a double-stranded DNA virus that causes monkeypox in humans and other animals. It belongs to the
Creative Diagnostics Launches Antibody-dependent Enhancement Assay Services
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. Flow cytometry, plaque assay or qPCR method are used to evaluate the ADE effect of test articles on virus infection in Fc receptor bearing cells. Antibody-dependent enhancement mainly refers to effects in the body caused by pathogen infection. In 1964, Hawkes and his team at the Australian National
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV vaccine development. Nipah virus (NiV) was initially isolated and identified in 1999 during an outbreak
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. Staphylococcus aureus is a Gram-positive spherical bacterium about 1

All 5 Releases

More Releases for R&D

Siveco doubles China R&D investment
On July 3, 2019, Siveco China held its half-year management meeting at the prestigious Hellas House in Shanghai, a nod to the company's continuing growth on the Belt & Road. With financial results above target, high customer satisfaction (as shown in the latest audited customer satisfaction survey) and a sales pipeline more promising than ever, the company's management board announced that shareholders have approved its request for additional investment in
R&D Collaborative Projects by GD Rectifiers
GD Rectifiers have extensive experience in collaborative R&D projects and are proud to work with some of the UK’s pioneering power electronic companies to drive design and innovation forward. This R&D service helps drive GD Rectifiers forward as a cutting edge manufacturer embracing fundamental technologies that support product development that contribute to next generation products throughout: renewable energy, embedded systems, smart metrering and the rail industry. Power Assemblies, Controllers and
Transforming Pharmaceutical R&D with Data
ReportsWorldwide has announced the addition of a new report title Transforming Pharmaceutical R&D with Data to its growing collection of premium market research reports. Transforming Pharmaceutical R&D with Data In the current drug pricing environment, biopharmaceutical firms cannot afford to continue spending billions of dollars on development programs that are more than 90% likely to fail. Raising prices to compensate for expensive, risky research and development (R&D) is no longer an option
Noliac is expanding the R&D team
Noliac is looking for two new colleagues for the R&D team in Prague, Czech Republic: A Precision/Fine Mechanics and an Electroengineer. Precision/Fine Mechanics For the R&D team in Prague, Czech Republic, Noliac is looking for a Precision/Fine mechanics to work on modifying existing products and work with developing new. Noliac requires a colleague who: Is mechanically skilled with a focus on very small machinery. Holds a technical high school degree or an apprenticeship
Leiber GmbH further invests in R&D
Since February 2016, Leiber GmbH has been reinforced by Dr med vet Claudia Westfahl - a veterinarian specialized in animal nutrition - as part of the company's strategy to invest in new product developments. With the new position ‘Product Development Animal Nutrition’, Dr Westfahl is responsible for new product development in the field of functional feed ingredients for both pet as well as farm animals. After graduating at the University
Rising R&D Funding for Nanotechnology
Global nanotechnology market has been registering marked increase in funds allocation by the countries across the world, especially with new product development that received huge momentum due to these funding. An increase in global public funding for R&D initiatives supports quick commercialization of nano-based products. Fundings from governments, corporations, and venture capital exhibited a CAGR growth of 1% during 2008-2012. In future, it is expected that nanotechnology funding will grow